Anosmia (Poor Sense Of Taste Or Smell)Family PracticeNursingInternal MedicineCritical CareEmergency MedicineOtolaryngologyEar Nose And ThroatAnosmiaInfectious DiseaseCoronavirus
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, April 29, 2020 (HealthDay News) -- Quantitative smell testing shows that decreased smell function is a major marker for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published online April 17 in the International Forum of Allergy & Rhinology.
Shima T. Moein, M.D., Ph.D., from the Institute for Research in Fundamental Sciences in Tehran, Iran, and colleagues administered the University of Pennsylvania Smell Identification Test (UPSIT), a validated 40-odorant test, to 60 confirmed COVID-19 inpatients and 60 age- and sex-matched controls to evaluate the magnitude and frequency of their olfactory dysfunction.
The researchers found that 98 percent of the COVID-19 patients exhibited some smell dysfunction (mean UPSIT score, 20.98 versus 34.10 in controls; P < 0.0001). More than half of the patients (58 percent) were anosmic (25 percent) or severely microsmic (33 percent), while 27 percent exhibited moderate microsmia and 13 percent mild microsmia. Only one patient (2 percent) showed normosmia. Patients showed deficits on all 40 UPSIT odorants. The researchers found no significant associations between test scores and sex, disease severity, or comorbidities.
"Quantitative smell testing demonstrates that decreased smell function, but not always anosmia, is a major marker for SARS-CoV-2 infection and suggests the possibility that smell testing may help, in some cases, to identify COVID-19 patients in need of early treatment or quarantine," conclude the authors.
One author reports financial ties to the pharmaceutical and medical device industry, including Sensonics International, the manufacturer and distributor of the smell test used in the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 26, 2022
Read this Next
Other Trending Articles